The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment
This trial is active, not recruiting.
|Condition||coronary heart disease|
|Sponsor||Cardiovascular Institute & Fuwai Hospital|
|Collaborator||Ministry of Science and Technology of the People´s Republic of China|
|Start date||February 2012|
|End date||October 2013|
|Trial size||400 participants|
|Trial identifier||NCT01543308, 2011-HDL-01|
The protein composition of HDL is complicated. The investigators have identified 40 distinct proteins associated with HDL by proteomics technology, and these proteins have been confirmed to be related to the function of anti-inflammation, anti-oxidation, improvement of endothelial function, inhibition of thrombosis and so on. And the investigators also found that the levels of some proteins in HDL changed in patients with coronary heart disease, compared with the healthy control group.
So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.
|Observational model||case control|
Differential Proteins and the levels of Differential Proteins
time frame: up to 3 years
Male or female participants from 18 years up to 75 years old.
Inclusion Criteria: Angiographic evidence of coronary artery disease, and no lipid-lowering therapy in the past 2 weeks for treatment group; Exclusion Criteria: - Use of potent lipid-lowering therapy for more than 2 weeks; myocardial infarction or percutaneous coronary intervention in the past 6 months; severe congestive heart failure, valvular heart disease and other non-coronary heart disease cardiovascular disease; liver or renal dysfunction; connective tissue disease; infection, Malignancy; and other conditions that physicians considered inappropriate to the study.
|Official title||Phase 1 Study of Coronary Heart Disease Proteomics Research|
|Principal investigator||Hong Liu|
Call for more information